5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione sodium salt manufacturers
|
| | 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione sodium salt Basic information |
| Product Name: | 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione sodium salt | | Synonyms: | 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione sodium salt;5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzylidine]-2,4-thiazolidinedione Sodium;sodiuM 5-[(4-{2-[Methyl(pyridin-2-yl)aMino]ethoxy}phenyl)Methyl]-1,3-thiazolidine-2,4-dione;UNII:YR4MBO751R;sodium,5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy;5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione;rosiglitazone sodium;Rosiglitazone sodium: No | | CAS: | 316371-83-2 | | MF: | C18H18N3NaO3S | | MW: | 379.40859 | | EINECS: | | | Product Categories: | | | Mol File: | 316371-83-2.mol |  |
| | 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione sodium salt Chemical Properties |
| storage temp. | Sealed in dry,Room Temperature | | InChI | InChI=1S/C18H19N3O3S.Na/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;/h2-9,15H,10-12H2,1H3,(H,20,22,23);/q;+1/p-1 | | InChIKey | XFOHHIYSRDUSCX-UHFFFAOYSA-M | | SMILES | N1([Na])C(=O)C(CC2C=CC(=CC=2)OCCN(C)C2=CC=CC=N2)SC1=O |
| | 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione sodium salt Usage And Synthesis |
| Uses | Rosiglitazone sodium is a potent and selective activator of PPARγ, with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of appr 40 nM for PPARγ; Rosiglitazone sodium is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5). | | in vivo | Rosiglitazone (5 mg/kg, p.o.) decreases the serum glucose in diabetic rats. Rosiglitazone also decreases IL-6, TNF-α, and VCAM-1 levels in diabetic group. Rosiglitazone in combination with losartan increases glucose compared to diabetic and Los-treated groups. Rosiglitazone significantly ameliorates endothelial dysfunction indicated by a significantly lower contractile response to PE and Ang II and enhancement of ACh-provoked relaxation in aortas isolated from diabetic rats[5]. | | IC 50 | PPARγ1: 30 nM (EC50); PPARγ2: 100 nM (EC50) | | References | [1] Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6. DOI:10.1074/jbc.270.22.12953
[2] Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8. DOI:10.1021/jm950395a
[3] Thouennon E, et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug;134(3):463-70. DOI:10.1111/jnc.13152
[4] Majeed Y, et al. Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol. 2011 Jun;79(6):1023-30. DOI:10.1124/mol.110.069922
[5] Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220. DOI:10.1139/cjpp-2017-0332 |
| | 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione sodium salt Preparation Products And Raw materials |
|